Literature DB >> 23570879

Myotonic dystrophy type 1 (DM1): a triplet repeat expansion disorder.

Ashok Kumar, Sarita Agarwal, Divya Agarwal, Shubha R Phadke.   

Abstract

Myotonic dystrophy is a progressive multisystem genetic disorder affecting about 1 in 8000 people worldwide. The unstable repeat expansions of (CTG)n or (CCTG)n in the DMPK and ZNF9 genes cause the two known subtypes of myotonic dystrophy: (i) myotonic dystrophy type 1 (DM1) and (ii) myotonic dystrophy type 2 (DM2) respectively. There is currently no cure but supportive management helps equally to reduce the morbidity and mortality and patients need close follow up to pay attention to their clinical problems. This review will focus on the clinical features, molecular view and genetics, diagnosis and management of DM1.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23570879     DOI: 10.1016/j.gene.2013.03.059

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  12 in total

1.  Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: A longitudinal case series study.

Authors:  Renata Conforti; Mario de Cristofaro; Adriana Cristofano; Barbara Brogna; Angela Sardaro; Gioacchino Tedeschi; Sossio Cirillo; Alfonso Di Costanzo
Journal:  Neuroradiol J       Date:  2016-01-11

Review 2.  Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.

Authors:  Seren Marsh; Britt Hanson; Matthew J A Wood; Miguel A Varela; Thomas C Roberts
Journal:  Mol Ther       Date:  2020-10-14       Impact factor: 11.454

3.  On the Applicability of Elastic Network Models for the Study of RNA CUG Trinucleotide Repeat Overexpansion.

Authors:  Àlex L González; Jordi Teixidó; José I Borrell; Roger Estrada-Tejedor
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

4.  A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.

Authors:  Fan Zhang; Nicole E Bodycombe; Keith M Haskell; Yumei L Sun; Eric T Wang; Carl A Morris; Lyn H Jones; Lauren D Wood; Mathew T Pletcher
Journal:  Hum Mol Genet       Date:  2017-08-15       Impact factor: 6.150

5.  Investigation of the molecular mechanisms underlying myotonic dystrophy types 1 and 2 cataracts using microRNA‑target gene networks.

Authors:  Dewang Shao; Xiaoquan Zhu; Wei Sun; Lu Huo; Wei Chen; Hua Wang; Bing Liu; Peng Pan
Journal:  Mol Med Rep       Date:  2017-07-21       Impact factor: 2.952

6.  The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1.

Authors:  Ranjan Batra; David A Nelles; Daniela M Roth; Florian Krach; Curtis A Nutter; Takahiro Tadokoro; James D Thomas; Łukasz J Sznajder; Steven M Blue; Haydee L Gutierrez; Patrick Liu; Stefan Aigner; Oleksandr Platoshyn; Atsushi Miyanohara; Martin Marsala; Maurice S Swanson; Gene W Yeo
Journal:  Nat Biomed Eng       Date:  2020-09-14       Impact factor: 25.671

7.  Autonomic regulation in muscular dystrophy.

Authors:  Corrado Angelini; Rita Di Leo; Paola Cudia
Journal:  Front Physiol       Date:  2013-09-20       Impact factor: 4.566

Review 8.  Life without double-headed non-muscle myosin II motor proteins.

Authors:  Venkaiah Betapudi
Journal:  Front Chem       Date:  2014-07-07       Impact factor: 5.221

9.  Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.

Authors:  Guiying Chen; Akio Masuda; Hiroyuki Konishi; Bisei Ohkawara; Mikako Ito; Masanobu Kinoshita; Hiroshi Kiyama; Tohru Matsuura; Kinji Ohno
Journal:  Sci Rep       Date:  2016-04-29       Impact factor: 4.379

Review 10.  RNA Granules: A View from the RNA Perspective.

Authors:  Siran Tian; Harrison A Curnutte; Tatjana Trcek
Journal:  Molecules       Date:  2020-07-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.